Description

ANGIZEM CD 120 MG

Indications

ANGIZEM CD 120 MG is primarily indicated for the management of hypertension (high blood pressure) and the treatment of chronic stable angina (chest pain). It is often prescribed to patients who require long-term control of their blood pressure and angina symptoms. By effectively lowering blood pressure, ANGIZEM CD can help reduce the risk of cardiovascular events such as heart attacks and strokes.

Mechanism of Action

ANGIZEM CD contains Diltiazem as its active ingredient, which is classified as a calcium channel blocker. The mechanism of action involves the inhibition of calcium ions from entering the cardiac and smooth muscle cells through voltage-gated calcium channels. This action leads to relaxation of vascular smooth muscle, resulting in vasodilation (widening of blood vessels). Consequently, this reduces peripheral vascular resistance and lowers blood pressure. Additionally, Diltiazem decreases heart rate and myocardial contractility, which alleviates the workload on the heart and reduces oxygen demand, making it effective in treating angina.

Pharmacological Properties

ANGIZEM CD exhibits a unique pharmacokinetic profile characterized by its extended-release formulation, allowing for once-daily dosing. After oral administration, Diltiazem is absorbed rapidly, with peak plasma concentrations occurring within 2 to 4 hours. The drug undergoes extensive hepatic metabolism, primarily by cytochrome P450 enzymes, leading to the formation of active metabolites. The elimination half-life of Diltiazem is approximately 3 to 5 hours, but the extended-release formulation provides a sustained therapeutic effect over 24 hours. The drug is primarily excreted in the urine, both as unchanged drug and metabolites.

Contraindications

ANGIZEM CD is contraindicated in patients with known hypersensitivity to Diltiazem or any of the excipients in the formulation. It should not be used in patients with severe hypotension (systolic blood pressure <90 mmHg), advanced aortic stenosis, or in individuals with a history of sick sinus syndrome or second- or third-degree atrioventricular block, unless a functioning pacemaker is present. Caution is advised in patients with heart failure, as Diltiazem may exacerbate this condition.

Side Effects

Common side effects associated with ANGIZEM CD include dizziness, headache, fatigue, and gastrointestinal disturbances such as nausea and constipation. Patients may also experience peripheral edema due to vasodilation effects. Less frequently, serious adverse effects may occur, including bradycardia (slow heart rate), hypotension, and liver enzyme elevations. It is essential for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of ANGIZEM CD for adults is typically 120 mg once daily. Depending on the patient’s response and clinical condition, the dosage may be titrated to a maximum of 240 mg per day. It is crucial to take the medication at the same time each day to maintain consistent blood levels. The capsules should be swallowed whole and not crushed or chewed to ensure the extended-release properties are preserved. Patients should be monitored regularly for blood pressure and heart rate to assess the effectiveness of the treatment and make necessary adjustments.

Interactions

ANGIZEM CD may interact with several medications, which can alter its effectiveness or increase the risk of adverse effects. Notably, co-administration with other antihypertensive agents may lead to additive hypotensive effects. Caution should be exercised when using Diltiazem with beta-blockers, as this combination may increase the risk of bradycardia and heart block. Additionally, CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase Diltiazem levels, while CYP3A4 inducers (e.g., rifampin) may decrease its effectiveness. Patients should inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements.

Precautions

Before initiating treatment with ANGIZEM CD, a thorough medical history should be obtained, particularly regarding cardiovascular status, liver function, and any history of drug allergies. Patients with renal impairment should be monitored closely, as Diltiazem is primarily excreted via the kidneys. It is also essential to assess the potential for drug interactions, especially in older adults who may be taking multiple medications. Patients should be advised to avoid abrupt discontinuation of the medication, as this may lead to rebound hypertension or exacerbation of angina symptoms.

Clinical Studies

Clinical studies have demonstrated the efficacy of ANGIZEM CD in lowering blood pressure and reducing the frequency and severity of angina attacks. In a randomized controlled trial, patients treated with Diltiazem showed significant reductions in systolic and diastolic blood pressure compared to placebo. Another study highlighted the drug’s ability to improve exercise tolerance in patients with chronic stable angina. These findings support the use of ANGIZEM CD as an effective therapeutic option for managing hypertension and angina, contributing to improved quality of life for patients.

Conclusion

ANGIZEM CD 120 MG is a well-established medication for the treatment of hypertension and chronic stable angina. Its unique extended-release formulation allows for convenient once-daily dosing, making it a suitable option for long-term management. Understanding the pharmacological properties, potential side effects, and drug interactions associated with ANGIZEM CD is essential for optimizing patient outcomes. As with any medication, it is crucial for patients to adhere to their prescribed regimen and maintain regular follow-up with their healthcare provider to ensure safe and effective treatment.